Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cimzia, Tysabri get CHMP negative opinions

EMEA's CHMP issued negative opinions on two MAAs for Crohn's disease: Cimzia certolizumab from UCB (Euronext:UCB) and Tysabri natalizumab from Elan (ELN) and Biogen

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE